[FORM 8-K CURRENT REPORT Date of Report (Date of Earliest event Reported): July 20, 2011(July 14, 2011) INC. THT HEAT TRANSFER TECHNOLOGY, Nevada 001-34812 20-5463509 (State or other jurisdiction of (IRS Employer Identification No.) incorporation or organization) THT Industrial Park No.5 Nanhuan Road, Tiexi District Siping, Jilin Province 136000 People's Republic of China 86-434-3265241 (Former name or former address, if]
[FORM 8-K CURRENT REPORT Date of Report (Date of Earliest event Reported): July 20, 2011(July 14, 2011) INC. THT HEAT TRANSFER TECHNOLOGY, Nevada 001-34812 20-5463509 (State or other jurisdiction of (IRS Employer Identification No.) incorporation or organization) THT Industrial Park No.5 Nanhuan Road, Tiexi District Siping, Jilin Province 136000 People's Republic of China 86-434-3265241 (Former name or former address, if]
[Sinovac Holds 2011 Annual Shareholders Meeting Press Release Source: Sinovac Biotech Ltd. On Thursday July 14, 2011, 8:00 am EDT BEIJING, July 14, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq:SVA - News), a leading provider of biopharmaceutical products in China, announced today that it held its 2011 Annual Shareholders Meeting on Thursday, July 14, 2011 at 9:00 a.m. Beijing Time.] [Amendments to the By-Laws of the Company 1 The existing By-Laws of the Company (as last amended on March 31, 2006) shall be amended by adding a definition of “special resolution,” and replacing the definition of “ordinary resolution” and Section 7.8 as follows: “ORDINARY RESOLUTION SPECIAL RESOLUTION 7.8 Votes of Shareholders Subject to any rights or restrictions for the time] [SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Road Haidian District Beijing 100085, People’s Republic of China x o Form 20-F SINOVAC BIOTECH LTD.]
[Sinovac Holds 2011 Annual Shareholders Meeting Press Release Source: Sinovac Biotech Ltd. On Thursday July 14, 2011, 8:00 am EDT BEIJING, July 14, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq:SVA - News), a leading provider of biopharmaceutical products in China, announced today that it held its 2011 Annual Shareholders Meeting on Thursday, July 14, 2011 at 9:00 a.m. Beijing Time.] [Amendments to the By-Laws of the Company 1 The existing By-Laws of the Company (as last amended on March 31, 2006) shall be amended by adding a definition of “special resolution,” and replacing the definition of “ordinary resolution” and Section 7.8 as follows: “ORDINARY RESOLUTION SPECIAL RESOLUTION 7.8 Votes of Shareholders Subject to any rights or restrictions for the time] [SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Road Haidian District Beijing 100085, People’s Republic of China x o Form 20-F SINOVAC BIOTECH LTD.]
[Sinovac Reports Positive Phase I Clinical Trial Results for EV71 Vaccine Candidate Against Hand, Foot & Mouth Disease(HFMD) – SVA News BEIJING, May 25, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NASDAQ: The phase II clinical trial is scheduled to be commenced within one or two months. The purpose for the Phase II study is to evaluate safety and tolerance of] [Sinovac Commences Phase II Clinical Trial for EV71 Vaccine BEIJING, June 28, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today the commencement of the Phase II clinical trial for its proprietary inactivated EV71 vaccine against Hand, Foot and Mouth Disease (HFMD). The safety observation results from the EV71 vaccine Phase] [SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Road Haidian District Beijing 100085, People’s Republic of China x o Form 20-F SINOVAC BIOTECH LTD.]
[Sinovac Reports Positive Phase I Clinical Trial Results for EV71 Vaccine Candidate Against Hand, Foot & Mouth Disease(HFMD) – SVA News BEIJING, May 25, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NASDAQ: The phase II clinical trial is scheduled to be commenced within one or two months. The purpose for the Phase II study is to evaluate safety and tolerance of] [Sinovac Commences Phase II Clinical Trial for EV71 Vaccine BEIJING, June 28, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today the commencement of the Phase II clinical trial for its proprietary inactivated EV71 vaccine against Hand, Foot and Mouth Disease (HFMD). The safety observation results from the EV71 vaccine Phase] [SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Road Haidian District Beijing 100085, People’s Republic of China x o Form 20-F SINOVAC BIOTECH LTD.]
[This Form 6-K consists of: JA Solar Appoints Min Cao to Succeed Anthea Chung as Chief Financial Officer SHANGHAI, July 13, 2011--- JA Solar Holdings Co., Ltd., (NASDAQ: JASO) ("JA Solar" or the "Company"), one of the world’s largest manufacturers of high-performance solar cells and solar power products, today announced that Mr. Min Cao will succeed Ms. Anthea Chung as]
[1. Names of Reporting Persons. CRCM Institutional Master Fund (BVI), Ltd. 2. Check the Appropriate Box if a Member of a Group (See Instructions) o (a) x ** (b) 3. SEC Use Only 4. WC Source of Funds (See Instructions) 5. o 6. Citizenship or Place of Organization British Virgin Islands]
